

Mary O'Brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490713/publications.pdf>

Version: 2024-02-01

27
papers

10,470
citations

516710

16
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

13323
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence—Enabled Studies of Acute Phosphoproteomic Changes. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1020-1029.	4.1	3
2	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. <i>European Journal of Cancer</i> , 2022, 171, 44-54.	2.8	14
3	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. <i>Lung Cancer</i> , 2021, 156, 147-150.	2.0	4
4	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT48.	1.5	7
5	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non—Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	1.6	468
6	Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC — The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. <i>Lung Cancer</i> , 2021, 161, 76-85.	2.0	4
7	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
8	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i> -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1396-1404.	4.1	14
9	Definition of Synchronous Oligometastatic Non—Small Cell Lung Cancer—A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
10	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.6	24
11	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non—Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	1.6	1,144
12	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non—Small Cell Lung Cancer: A Single-Center Experience. <i>Journal of Thoracic Oncology</i> , 2018, 13, 63-72.	1.1	21
13	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236.	3.7	31
14	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 799-811.	10.7	56
15	Looking back and to the future: Are we improving “cure”™ in non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2017, 75, 192-194.	2.8	13
16	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations — Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278.	2.8	22
17	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609.	10.7	282
18	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥ 50% enrolled in KEYNOTE-024.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9000-9000.	1.6	43

#	ARTICLE	IF	CITATIONS
19	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. European Journal of Cancer, 2016, 60, 26-39.	2.8	28
20	Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2016, 375, 1823-1833.	27.0	7,847
21	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE, 2015, 10, e0139074.	2.5	50
22	Development in the diagnostic lung cancer pathway: implication for treatment. Lung Cancer Management, 2014, 3, 417-428.	1.5	1
23	Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC). BMC Palliative Care, 2014, 13, 59.	1.8	42
24	Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature. Case Reports in Oncology, 2014, 7, 393-400.	0.7	10
25	Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Clinical Oncology, 2014, 32, 1882-1888.	1.6	106
26	Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.. Journal of Clinical Oncology, 2012, 30, 7081-7081.	1.6	1
27	Recent Advances with Topotecan in the Treatment of Lung Cancer. Oncologist, 2007, 12, 1194-1204.	3.7	38